Smart Health Shop Forum Blog: April 2014

Wednesday, April 30, 2014

UPDATE 1-WellPoint says first-quarter profit fell on reform costs

Wed Apr 30, 2014 6:40am EDT

 (Adds outlook)

 April 30 (Reuters) - WellPoint Inc, the second-largest U.S. health insurer, said on Wednesday that first-quarter profit fell, largely because of investment spending related to healthcare reform and the higher administrative costs of adding new commercial customers.

 WellPoint, which runs Anthem and Empire Blue Cross Blue Shield plans, reported net income of $701 million, or $2.40 per share, down from $885 million, or $2.89 per share, a year earlier.

 As in Aetna Inc's report last week, earnings beat analysts' expectations. Excluding net gains on investments, WellPoint's profit was $2.30 per share. Analysts on average had expected $2.12, according to Thomson Reuters I/B/E/S.

 The company said it had spent less on medical claims than expected.

 WellPoint raised its outlook for 2014 earnings by about 20 cents per share, saying that it now expects to earn at least $8.40, excluding items. During an investor day last month, the company gave an outlook of more than $8.20 per share.

 The company added 1.2 million members in its commercial business, which includes large national employers, local employers and the individual markets.

 WellPoint is selling individual policies on the new exchanges created under President Barack Obama's national healthcare reform law in the 14 states where it operates Blue Cross Blue Shield plans. (Reporting by Caroline Humer; Editing by Lisa Von Ahn)

Link this

Share this

Digg this

Reprints

via Smart Health Shop Forum http://ift.tt/1pNX49c

UK lawmakers plan to probe Pfizer pursuit of AstraZeneca

By Kylie MacLellan and Ben Hirschler

LONDON, April 30 Wed Apr 30, 2014 6:26am EDT

 LONDON, April 30 (Reuters) - British lawmakers intend to investigate U.S. drugmaker Pfizer's planned $100 billion takeover of British rival AstraZeneca in a bid to ensure scientific research and jobs are protected.

 Members of the parliamentary business, innovation and skills committee are worried that the deal, which would be the biggest-ever foreign acquisition of a British company, could threaten the country's strategic interests.

 "We are keen to look closely at it," committee member Ann McKechin told Reuters.

 "We will see how events pan out over the next few days, but clearly given the scale of the proposed merger it is important that we consider the impact not just on shareholders but also on employees and the wider interests of the UK."

 AstraZeneca, Britain's second-biggest drugmaker behind GlaxoSmithKline, is an important part of the life sciences sector and employs nearly 7,000 staff in the country.

 Politicians are wary of foreign takeovers in the light of Kraft's 2010 acquisition of Cadbury, when the U.S. food group promised to keep open a key factory, only to go back on the pledge soon after the deal was completed.

 "The committee previously had a great deal of concern over the Cadbury takeover, so I think this is one we will really have to closely analyse what is on offer," McKechin said.

 Pfizer already has a tarnished reputation in Britain after it announced plans in 2011 to shutter a major drug research site in Sandwich, southern England, where Viagra was invented, with the loss of nearly 2,000 jobs.

 The U.S. firm says it views Britain as an attractive location for both pharmaceutical research and manufacturing - helped by recent government tax incentives - but cannot make any firm commitments on future investment or jobs.

 Pfizer Chief Executive Ian Read is in Britain to lobby politicians and investors about his plans. The government has so far adopted a neutral stance on the matter, but behind the scenes officials are warning Pfizer against making draconian research job cuts, industry sources said.

 Pfizer has made two approaches to AstraZeneca, both of which have been rebuffed. The company is widely expected to come back with a revised offer before a May 26 deadline for it to "put up or shut up" under UK takeover rules. (Editing by David Holmes)

Link this

Share this

Digg this

Reprints

via Smart Health Shop Forum http://ift.tt/R2kMi0

WellPoint says first-quarter profit fell on reform costs

April 30 Wed Apr 30, 2014 6:14am EDT

April 30 (Reuters) - WellPoint Inc, the second-largest U.S. health insurer, said on Wednesday that first-quarter profit fell, largely because of investment spending related to healthcare reform and the higher administrative costs of adding new commercial customers.

WellPoint, which runs Anthem and Empire Blue Cross Blue Shield plans, reported net profit of $701 million, or $2.40 per share, down from $885 million, or $2.89 per share, a year earlier.

Excluding net gains of 10 cents per share, earnings were $2.30 per share.

Analysts on average had expected earnings of $2.12 per share, according to Thomson Reuters I/B/E/S. It was not immediately known if the figures were comparable. (Reporting by Caroline Humer; Editing by Lisa Von Ahn)

via Smart Health Shop Forum http://ift.tt/1pNX09a

Leading medics say UK in need of 'urgent referral' as country struggles to get to grips with obesity crisis

The UK is struggling to make inroads into the obesity epidemic that is gripping the nation, with no progress on improving nutritional standards in schools, restricting junk food advertising or...

via Smart Health Shop Forum http://ift.tt/1pNX20M

Adults with insomnia benefit from tart cherry juice

A morning and evening ritual of tart cherry juice may help you sleep better at night, suggests a new study presented at the Experimental Biology 2014 meeting.